Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
The Journal of Urology
|
September 28, 2013
Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer
Annelies Vellekoop, Stacy Loeb, Yasin Folkvaljon, et al.
Acta Oncologica (Stockholm, Sweden)
|
February 17, 2018
Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study
Urika Joneborg, Yasin Folkvaljon, Nikos Papadogiannakis, et al.
Journal of the National Cancer Institute
|
November 9, 2017
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
Stacy Loeb, Eugenio Ventimiglia, Andrea Salonia, et al.
The Journal of Urology
|
September 22, 2018
Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance
Stacy Loeb, Yasin Folkvaljon, Ola Bratt, et al.
JAMA Oncology
|
October 22, 2016
Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden
Stacy Loeb, Yasin Folkvaljon, Caitlin Curnyn, et al.
BJU International
|
July 24, 2014
Upper limit of cancer extent on biopsy defining very low-risk prostate cancer
Ola Bratt, Yasin Folkvaljon, Stacy Loeb, et al.
European Urology
|
December 29, 2015
Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort
Stacy Loeb, Yasin Folkvaljon, David Robinson, et al.
European Urology
|
January 9, 2016
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
Stacy Loeb, Yasin Folkvaljon, David Robinson, et al.
Scandinavian Journal of Urology
|
October 27, 2018
Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden
Hampus Nugin, Yasin Folkvaljon, Jan-Erik Damber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2017
Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer
Stacy Loeb, Yasin Folkvaljon, Jan-Erik Damber, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
The Journal of Urology
|
September 28, 2013
Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer
Annelies Vellekoop, Stacy Loeb, Yasin Folkvaljon, et al.
Acta Oncologica (Stockholm, Sweden)
|
February 17, 2018
Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study
Urika Joneborg, Yasin Folkvaljon, Nikos Papadogiannakis, et al.
Journal of the National Cancer Institute
|
November 9, 2017
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
Stacy Loeb, Eugenio Ventimiglia, Andrea Salonia, et al.
The Journal of Urology
|
September 22, 2018
Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance
Stacy Loeb, Yasin Folkvaljon, Ola Bratt, et al.
JAMA Oncology
|
October 22, 2016
Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden
Stacy Loeb, Yasin Folkvaljon, Caitlin Curnyn, et al.
BJU International
|
July 24, 2014
Upper limit of cancer extent on biopsy defining very low-risk prostate cancer
Ola Bratt, Yasin Folkvaljon, Stacy Loeb, et al.
European Urology
|
December 29, 2015
Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort
Stacy Loeb, Yasin Folkvaljon, David Robinson, et al.
European Urology
|
January 9, 2016
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
Stacy Loeb, Yasin Folkvaljon, David Robinson, et al.
Scandinavian Journal of Urology
|
October 27, 2018
Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden
Hampus Nugin, Yasin Folkvaljon, Jan-Erik Damber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2017
Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer
Stacy Loeb, Yasin Folkvaljon, Jan-Erik Damber, et al.
Page
of 3